A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Systemic Lupus Erythematosus Patients With Active Disease.

Trial Profile

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Systemic Lupus Erythematosus Patients With Active Disease.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2012

At a glance

  • Drugs Fostamatinib (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Acronyms SOLEIL
  • Most Recent Events

    • 07 Jun 2011 Planned end date changed from 1 Feb 2010 to 1 Mar 2010 as reported by ClinicalTrials.gov.
    • 20 May 2010 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 09 Dec 2008 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top